LAS 34475

Drug Profile

LAS 34475

Latest Information Update: 24 Aug 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Almirall-Prodesfarma
  • Developer Almirall S.A.
  • Class Anti-inflammatories; Non-opioid analgesics; Oxazoles; Small molecules
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Osteoarthritis; Pain

Most Recent Events

  • 20 Jun 2003 Phase-II/III clinical trials in Osteoarthritis in Spain (PO)
  • 20 Jun 2003 Phase-II/III clinical trials in Osteoarthritis in USA (PO)
  • 20 Jun 2003 Data presented at the 4th Annual European Congress of Rheumatology (EULAR-2003) have been added to the pharmacokinetics, adverse events and Rheumatic disease pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top